Fathom Therapeutics Raises $55M to Advance Drug Pipeline
Fathom Therapeutics raised $55M Series A led by Sutter Hill Ventures to advance its AI-powered drug discovery pipeline.
The big picture: Fathom Therapeutics, a New York-based biotechnology company, has appointed Bret Williams, Ph.D., as Chief Scientific Officer. This key leadership addition follows the company’s $55 million Series A financing in May 2026 and signals a strategic shift towards translating its quantum chemistry and artificial intelligence platform into preclinical and clinical development programs.
Why it matters:
- Strategic Pivot: Williams’ appointment underscores Fathom’s transition from purely computational drug discovery to actively advancing drug candidates into therapeutic programs, leveraging its recent Series A funding.
- Experienced Leadership: Williams brings over two decades of experience in drug discovery and translational research, which is critical for guiding Fathom’s pipeline from initial target identification through to clinical development.
- Addressing Challenging Targets: The company’s Microcosmos platform aims to develop small-molecule medicines for proteins and biological mechanisms that have historically been difficult to address with conventional drug discovery methods.
How it works:
- Microcosmos Platform: Fathom’s proprietary technology utilizes physics-based simulations and AI to model protein motion and molecular interactions at atomic resolution.
- Targeted Drug Design: The platform is engineered to identify molecules with precise therapeutic effects while minimizing unintended interactions with other biological targets.
- Pipeline Advancement: As CSO, Williams will oversee the selection and progression of promising compounds designed through Microcosmos into Fathom’s internal development pipeline and external research partnerships.
The catch: The AI drug discovery sector is highly competitive, with numerous well-funded companies vying to translate computational insights into clinical success. Fathom Therapeutics must rapidly demonstrate the efficacy and safety of its platform-generated candidates to stand out, requiring robust preclinical validation and efficient clinical trial execution.
Key Facts
- Company: Fathom Therapeutics
- Amount: $55M
- Round: Series A
- Investors: Sutter Hill Ventures (lead), Lilly Ventures
- Founder: Huafeng Xu
- Sector: AI Drug Discovery
- Headquarters: New York
AIPressRoom Weekly
Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.